Tibet Rhodiola Pharmaceutical Holding Co. Logo

Tibet Rhodiola Pharmaceutical Holding Co.

600211.SS

(3.2)
Stock Price

37,95 CNY

16.13% ROA

23.3% ROE

17.34x PER

Market Cap.

14.356.088.260,00 CNY

19.74% DER

3.83% Yield

28.61% NPM

Tibet Rhodiola Pharmaceutical Holding Co. Stock Analysis

Tibet Rhodiola Pharmaceutical Holding Co. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Tibet Rhodiola Pharmaceutical Holding Co. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (23.68%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

3 DER

The stock has a minimal amount of debt (22%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Assets Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

5 Dividend

Investors can take comfort in the company's unwavering commitment to dividends, as it has consistently distributed payouts over the past five years, ensuring a reliable income stream.

6 Revenue Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

7 Net Profit Growth

This company's net profit has been consistently on the rise over the past three years, indicating a strong financial performance and making it an appealing investment opportunity.

8 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (159) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

9 PBV

The stock's elevated P/BV ratio (3.78x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

10 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

11 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

Tibet Rhodiola Pharmaceutical Holding Co. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Tibet Rhodiola Pharmaceutical Holding Co. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Tibet Rhodiola Pharmaceutical Holding Co. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Tibet Rhodiola Pharmaceutical Holding Co. Revenue
Year Revenue Growth
1996 21.658.576
1997 48.290.409 55.15%
1998 78.045.310 38.13%
1999 82.966.800 5.93%
2000 83.122.877 0.19%
2001 74.659.338 -11.34%
2002 74.490.534 -0.23%
2003 75.079.508 0.78%
2004 182.662.148 58.9%
2005 696.482.195 73.77%
2006 861.841.830 19.19%
2007 823.237.884 -4.69%
2008 991.069.964 16.93%
2009 1.109.621.075 10.68%
2010 1.110.729.268 0.1%
2011 1.079.038.019 -2.94%
2012 1.221.385.421 11.65%
2013 1.402.221.159 12.9%
2014 1.668.036.041 15.94%
2015 1.382.755.815 -20.63%
2016 796.806.691 -73.54%
2017 915.625.717 12.98%
2018 1.027.879.210 10.92%
2019 1.256.021.957 18.16%
2020 1.373.105.105 8.53%
2021 2.138.586.552 35.79%
2022 2.554.609.066 16.29%
2023 2.191.091.694 -16.59%
2023 3.096.160.811 29.23%
2024 3.574.039.992 13.37%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Tibet Rhodiola Pharmaceutical Holding Co. Research and Development Expenses
Year Research and Development Expenses Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 1.619.551 100%
2011 3.649.526 55.62%
2012 1.377.365 -164.96%
2013 2.686.391 48.73%
2014 2.822.621 4.83%
2015 4.161.536 32.17%
2016 7.483.532 44.39%
2017 4.158.381 -79.96%
2018 8.207.689 49.34%
2019 11.074.371 25.89%
2020 7.459.290 -48.46%
2021 60.857.486 87.74%
2022 88.130.459 30.95%
2023 1.964.185 -4386.87%
2023 14.848.620 86.77%
2024 26.573.732 44.12%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Tibet Rhodiola Pharmaceutical Holding Co. General and Administrative Expenses
Year General and Administrative Expenses Growth
1996 2.059.654
1997 2.758.979 25.35%
1998 3.692.707 25.29%
1999 8.662.910 57.37%
2000 13.251.818 34.63%
2001 16.364.883 19.02%
2002 16.453.964 0.54%
2003 20.670.741 20.4%
2004 27.366.903 24.47%
2005 56.061.794 51.18%
2006 37.963.993 -47.67%
2007 43.160.334 12.04%
2008 32.395.633 -33.23%
2009 33.913.608 4.48%
2010 13.382.109 -153.42%
2011 13.863.260 3.47%
2012 12.831.303 -8.04%
2013 13.183.752 2.67%
2014 18.383.747 28.29%
2015 14.081.139 -30.56%
2016 16.542.978 14.88%
2017 24.830.807 33.38%
2018 27.929.455 11.09%
2019 31.773.602 12.1%
2020 34.652.337 8.31%
2021 44.440.221 22.02%
2022 47.746.786 6.93%
2023 259.624.144 81.61%
2023 48.929.566 -430.61%
2024 -35.712.811 237.01%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Tibet Rhodiola Pharmaceutical Holding Co. EBITDA
Year EBITDA Growth
1996 6.527.962
1997 20.336.126 67.9%
1998 32.745.033 37.9%
1999 32.713.618 -0.1%
2000 39.757.968 17.72%
2001 27.318.726 -45.53%
2002 25.431.810 -7.42%
2003 29.928.483 15.02%
2004 30.640.434 2.32%
2005 -10.179.924 400.99%
2006 36.393.640 127.97%
2007 -24.457.571 248.8%
2008 34.261.631 171.38%
2009 13.176.754 -160.02%
2010 53.429.966 75.34%
2011 46.626.519 -14.59%
2012 67.478.880 30.9%
2013 66.395.699 -1.63%
2014 57.571.648 -15.33%
2015 123.258.345 53.29%
2016 291.051.977 57.65%
2017 363.011.234 19.82%
2018 407.999.629 11.03%
2019 432.811.657 5.73%
2020 547.657.682 20.97%
2021 646.695.298 15.31%
2022 837.271.758 22.76%
2023 1.178.961.223 28.98%
2023 1.101.135.790 -7.07%
2024 1.325.793.280 16.95%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Tibet Rhodiola Pharmaceutical Holding Co. Gross Profit
Year Gross Profit Growth
1996 16.510.583
1997 39.647.915 58.36%
1998 67.145.790 40.95%
1999 67.134.516 -0.02%
2000 69.360.207 3.21%
2001 65.102.936 -6.54%
2002 60.527.375 -7.56%
2003 57.452.166 -5.35%
2004 83.709.626 31.37%
2005 117.961.878 29.04%
2006 222.674.511 47.02%
2007 101.013.297 -120.44%
2008 149.551.400 32.46%
2009 188.503.500 20.66%
2010 191.894.816 1.77%
2011 193.870.781 1.02%
2012 243.370.906 20.34%
2013 279.763.613 13.01%
2014 339.720.842 17.65%
2015 447.290.907 24.05%
2016 608.231.135 26.46%
2017 676.045.490 10.03%
2018 821.505.806 17.71%
2019 1.049.378.966 21.72%
2020 1.178.140.144 10.93%
2021 1.915.368.263 38.49%
2022 2.407.914.731 20.46%
2023 2.055.358.596 -17.15%
2023 2.915.088.033 29.49%
2024 3.406.840.680 14.43%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Tibet Rhodiola Pharmaceutical Holding Co. Net Profit
Year Net Profit Growth
1996 5.596.533
1997 19.878.281 71.85%
1998 31.929.644 37.74%
1999 33.074.986 3.46%
2000 35.721.759 7.41%
2001 18.298.830 -95.21%
2002 10.197.512 -79.44%
2003 5.774.951 -76.58%
2004 6.081.282 5.04%
2005 -41.323.964 114.72%
2006 3.077.274 1442.88%
2007 -125.269.434 102.46%
2008 6.486.264 2031.3%
2009 19.087.067 66.02%
2010 23.556.576 18.97%
2011 20.514.329 -14.83%
2012 30.530.181 32.81%
2013 27.153.180 -12.44%
2014 20.979.870 -29.42%
2015 91.635.772 77.11%
2016 198.289.475 53.79%
2017 229.645.747 13.65%
2018 215.606.211 -6.51%
2019 312.321.254 30.97%
2020 418.095.830 25.3%
2021 208.938.062 -100.11%
2022 369.839.847 43.51%
2023 1.037.748.586 64.36%
2023 800.913.981 -29.57%
2024 1.240.870.436 35.46%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Tibet Rhodiola Pharmaceutical Holding Co. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 -1 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 1 100%
2020 2 0%
2021 1 0%
2022 1 100%
2023 4 75%
2023 3 -33.33%
2024 4 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Tibet Rhodiola Pharmaceutical Holding Co. Free Cashflow
Year Free Cashflow Growth
1999 -61.002.687
2000 -97.893.912 37.68%
2001 -64.247.897 -52.37%
2002 -69.287.881 7.27%
2003 24.329.831 384.79%
2004 9.455.781 -157.3%
2005 11.850.292 20.21%
2006 17.730.314 33.16%
2007 -35.671.982 149.7%
2008 16.657.212 314.15%
2009 14.182.498 -17.45%
2010 -677.712 2192.71%
2011 9.780.396 106.93%
2012 51.782.320 81.11%
2013 245.104.203 78.87%
2014 -169.326.777 244.75%
2015 123.266.525 237.37%
2016 240.563.928 48.76%
2017 -516.518.412 146.57%
2018 265.851.383 294.29%
2019 440.595.827 39.66%
2020 206.874.960 -112.98%
2021 -59.047.763 450.35%
2022 735.413.833 108.03%
2023 1.060.449.273 30.65%
2023 233.125.926 -354.88%
2024 154.268.325 -51.12%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Tibet Rhodiola Pharmaceutical Holding Co. Operating Cashflow
Year Operating Cashflow Growth
1999 2.246.631
2000 20.555.027 89.07%
2001 15.473.520 -32.84%
2002 32.854.146 52.9%
2003 47.205.277 30.4%
2004 26.904.343 -75.46%
2005 18.918.704 -42.21%
2006 33.629.555 43.74%
2007 -18.295.360 283.81%
2008 21.457.337 185.26%
2009 17.884.257 -19.98%
2010 1.900.169 -841.19%
2011 12.090.452 84.28%
2012 56.200.572 78.49%
2013 279.222.005 79.87%
2014 -141.403.348 297.46%
2015 133.930.272 205.58%
2016 250.204.859 46.47%
2017 91.457.114 -173.58%
2018 289.217.375 68.38%
2019 489.592.488 40.93%
2020 428.165.608 -14.35%
2021 366.531.412 -16.82%
2022 837.377.038 56.23%
2023 1.082.137.896 22.62%
2023 238.432.419 -353.86%
2024 163.114.462 -46.17%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Tibet Rhodiola Pharmaceutical Holding Co. Capital Expenditure
Year Capital Expenditure Growth
1999 63.249.318
2000 118.448.939 46.6%
2001 79.721.417 -48.58%
2002 102.142.027 21.95%
2003 22.875.445 -346.51%
2004 17.448.562 -31.1%
2005 7.068.411 -146.85%
2006 15.899.240 55.54%
2007 17.376.622 8.5%
2008 4.800.125 -262%
2009 3.701.758 -29.67%
2010 2.577.881 -43.6%
2011 2.310.056 -11.59%
2012 4.418.252 47.72%
2013 34.117.801 87.05%
2014 27.923.429 -22.18%
2015 10.663.747 -161.85%
2016 9.640.931 -10.61%
2017 607.975.526 98.41%
2018 23.365.992 -2501.97%
2019 48.996.661 52.31%
2020 221.290.647 77.86%
2021 425.579.175 48%
2022 101.963.204 -317.39%
2023 21.688.623 -370.12%
2023 5.306.494 -308.72%
2024 8.846.137 40.01%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Tibet Rhodiola Pharmaceutical Holding Co. Equity
Year Equity Growth
1996 17.897.002
1997 85.340.000 79.03%
1998 100.978.646 15.49%
1999 389.708.661 74.09%
2000 402.348.462 3.14%
2001 406.502.475 1.02%
2002 418.847.087 2.95%
2003 424.534.641 1.34%
2004 435.510.924 2.52%
2005 393.251.048 -10.75%
2006 396.343.570 0.78%
2007 274.282.355 -44.5%
2008 279.152.993 1.74%
2009 299.997.932 6.95%
2010 324.188.155 7.46%
2011 354.935.733 8.66%
2012 385.434.240 7.91%
2013 399.204.389 3.45%
2014 414.183.513 3.62%
2015 485.900.282 14.76%
2016 658.189.748 26.18%
2017 2.045.402.776 67.82%
2018 2.257.157.229 9.38%
2019 2.446.790.290 7.75%
2020 2.588.381.948 5.47%
2021 2.645.020.322 2.14%
2022 3.030.770.799 12.73%
2023 3.373.620.712 10.16%
2023 3.446.261.388 2.11%
2024 3.825.147.988 9.91%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Tibet Rhodiola Pharmaceutical Holding Co. Assets
Year Assets Growth
1996 47.175.077
1997 119.662.876 60.58%
1998 172.656.099 30.69%
1999 436.441.044 60.44%
2000 528.360.907 17.4%
2001 608.325.276 13.15%
2002 733.078.599 17.02%
2003 754.356.220 2.82%
2004 777.253.387 2.95%
2005 820.620.453 5.28%
2006 866.901.919 5.34%
2007 831.963.195 -4.2%
2008 829.661.464 -0.28%
2009 743.702.854 -11.56%
2010 735.469.374 -1.12%
2011 787.864.289 6.65%
2012 845.150.699 6.78%
2013 1.137.460.592 25.7%
2014 1.046.443.662 -8.7%
2015 706.330.005 -48.15%
2016 2.290.679.446 69.17%
2017 2.330.044.648 1.69%
2018 2.532.051.965 7.98%
2019 2.767.231.426 8.5%
2020 2.944.288.278 6.01%
2021 3.802.655.776 22.57%
2022 4.099.412.305 7.24%
2023 4.587.357.109 10.64%
2023 4.721.414.663 2.84%
2024 5.335.753.554 11.51%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Tibet Rhodiola Pharmaceutical Holding Co. Liabilities
Year Liabilities Growth
1996 29.278.074
1997 34.322.876 14.7%
1998 71.677.452 52.11%
1999 46.732.383 -53.38%
2000 126.012.444 62.91%
2001 201.822.800 37.56%
2002 314.231.510 35.77%
2003 329.821.579 4.73%
2004 341.742.462 3.49%
2005 427.369.405 20.04%
2006 470.558.348 9.18%
2007 557.680.839 15.62%
2008 550.508.470 -1.3%
2009 443.704.921 -24.07%
2010 411.281.218 -7.88%
2011 432.928.555 5%
2012 459.716.457 5.83%
2013 738.256.201 37.73%
2014 632.260.148 -16.76%
2015 220.429.722 -186.83%
2016 1.632.489.697 86.5%
2017 284.641.871 -473.52%
2018 274.894.735 -3.55%
2019 320.441.135 14.21%
2020 355.906.330 9.96%
2021 1.157.635.453 69.26%
2022 1.068.641.506 -8.33%
2023 1.187.881.480 10.04%
2023 1.275.153.275 6.84%
2024 1.510.605.565 15.59%

Tibet Rhodiola Pharmaceutical Holding Co. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
8.98
Net Income per Share
2.57
Price to Earning Ratio
17.34x
Price To Sales Ratio
4.96x
POCF Ratio
12.76
PFCF Ratio
12.98
Price to Book Ratio
3.79
EV to Sales
4.83
EV Over EBITDA
13.52
EV to Operating CashFlow
12.43
EV to FreeCashFlow
12.64
Earnings Yield
0.06
FreeCashFlow Yield
0.08
Market Cap
14,36 Bil.
Enterprise Value
13,98 Bil.
Graham Number
26.08
Graham NetNet
7.12

Income Statement Metrics

Net Income per Share
2.57
Income Quality
1.36
ROE
0.23
Return On Assets
0.16
Return On Capital Employed
0.23
Net Income per EBT
0.89
EBT Per Ebit
1.05
Ebit per Revenue
0.31
Effective Tax Rate
0.1

Margins

Sales, General, & Administrative to Revenue
0.02
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.94
Operating Profit Margin
0.31
Pretax Profit Margin
0.32
Net Profit Margin
0.29

Dividends

Dividend Yield
0.04
Dividend Yield %
3.83
Payout Ratio
0.59
Dividend Per Share
1.7

Operating Metrics

Operating Cashflow per Share
3.49
Free CashFlow per Share
3.43
Capex to Operating CashFlow
0.02
Capex to Revenue
0.01
Capex to Depreciation
-8.89
Return on Invested Capital
0.18
Return on Tangible Assets
0.16
Days Sales Outstanding
120.84
Days Payables Outstanding
148.54
Days of Inventory on Hand
287.1
Receivables Turnover
3.02
Payables Turnover
2.46
Inventory Turnover
1.27
Capex per Share
0.06

Balance Sheet

Cash per Share
9,37
Book Value per Share
11,87
Tangible Book Value per Share
11.24
Shareholders Equity per Share
11.76
Interest Debt per Share
2.36
Debt to Equity
0.2
Debt to Assets
0.14
Net Debt to EBITDA
-0.36
Current Ratio
2.8
Tangible Asset Value
3,62 Bil.
Net Current Asset Value
2,62 Bil.
Invested Capital
3448622725
Working Capital
2,66 Bil.
Intangibles to Total Assets
0.04
Average Receivables
0,82 Bil.
Average Payables
0,05 Bil.
Average Inventory
119033537
Debt to Market Cap
0.05

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Tibet Rhodiola Pharmaceutical Holding Co. Dividends
Year Dividends Growth
2001 0
2002 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 1 0%
2019 0 0%
2020 1 100%
2021 1 0%
2022 0 0%
2023 3 100%
2024 2 -100%

Tibet Rhodiola Pharmaceutical Holding Co. Profile

About Tibet Rhodiola Pharmaceutical Holding Co.

Tibet Rhodiola Pharmaceutical Holding Co. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. It offers biological products, Tibetan medicine, Chinese medicine, and chemical medicine products. The company was founded in 1999 and is based in Lhasa, China.

CEO
Mr. Yuan Dong Guo
Employee
601
Address
No. 93, Beijing Middle Road
Lhasa, 850000

Tibet Rhodiola Pharmaceutical Holding Co. Executives & BODs

Tibet Rhodiola Pharmaceutical Holding Co. Executives & BODs
# Name Age
1 Ms. Lan Liu
Deputy GM & Secretary of the Board
70
2 Mr. Yuan Dong Guo
GM & Director
70
3 Mr. Jun Chen
Financial Director
70

Tibet Rhodiola Pharmaceutical Holding Co. Competitors